Ireland watchdog fee rise

Ireland’s medicines regulator won approval for higher 2026 fees on drug companies after warning that a heavier workload and rising costs were straining its budget. (businessplus.ie) The Health Products Regulatory Authority, or HPRA, asked for the increase in its 2026 fee consultation published on October 6, 2025, and said it reviews charges every year after consulting industry. The agency said it regulates human medicines authorisations, manufacturers and wholesalers without exchequer funding for those operations. (hpra.ie) (assets.hpra.ie) Business Plus reported on April 13, 2026, that Health Minister Jennifer Carroll MacNeill approved a 2.5% fee rise in December after officials warned of “significant” challenges for the authority in 2026. The same report said the minister was not given a cost-impact analysis of the likely effect on prices before signing off. (businessplus.ie) The fees matter because the HPRA sits at the front end of the medicines system: it authorises products, inspects manufacturers and wholesalers, and monitors safety issues after medicines reach the market. The agency’s 2024 annual report said it authorised 462 new human medicines, handled 7,885 suspected adverse reaction reports and carried out 83 good manufacturing practice inspections. (hpra.ie) (assets.hpra.ie) The HPRA said in its consultation paper that 2025 activity levels reached or exceeded the previous year and that 2026 would bring more work from new legislation and system changes. It cited the end of Brexit-related medicines exemptions, the Windsor Framework rules from January 2025 and broader project work across the agency. (assets.hpra.ie) Industry groups pushed back. Medicines for Ireland, which represents generic-drug manufacturers, said the higher charges would add pressure to a sector with tighter margins and could affect affordability and the sustainability of supply. (businessplus.ie) The HPRA’s consultation process drew only a handful of responses before it published the outcome on November 7, 2025. The regulator said it received three submissions on the human medicines, compliance and medical devices fee consultation, including two from industry representative groups and one from a marketing authorisation holder. (hpra.ie) (assets.hpra.ie) This is not a one-off change. The HPRA says it has run annual fee reviews since 2004, and Ireland’s 2024 fees regulations formally revised the schedule of charges payable to the authority under the Irish Medicines Board Act 1995. (assets.hpra.ie) (irishstatutebook.ie) The immediate question is whether higher regulatory charges stay inside company balance sheets or show up in medicine prices and supply decisions. The regulator argued the increase was needed to keep the oversight system funded; generic manufacturers said the extra cost lands on a market already under strain. (businessplus.ie)